Gemcitabine - A safety review

Anti-Cancer Drugs

Volumn 9, Issue 3, 1998, Pages 191-201

  Aapro, Matti S ^a   Martin, Christophe ^b   Hatty, Sarah ^c  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b BRISTOL MYERS SQUIBB   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Anticancer drug; Gemcitabine; Safety

Indexed keywords

GEMCITABINE; NUCLEOSIDE ANALOG;

ALLERGY; ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; LUNG TOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0031925359     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199803000-00001     Document Type: Review

References (41)

1. O'Rourke TJ, Brown T, Havlin K, Kuhn K. Phase I clinical trial of gemcitabine given as an intravenous bolus on five consecutive days. Eur J Cancer 1994; 30: 417-8.
2. Vermorken J, Guastalla JP, Hatty SR, et al. Phase I study of gemcitabine using a once every 2 week schedule. Br J Cancer 1997; 76 (suppl 11): 1489-93.
3. Poplin E, Redman B, Flaherty L, Woziak A. Difluorodeoxy cytidine (dFdC): a phase I study. Proc Am Soc Clin Oncol 1989; 30: 282.
4. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
5. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5: 182-4.
6. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and antitumor effect of 2′,2′-difluorodeoxycitidine (gemcitabine). Cancer Invest 1990; 8 (suppl 2): 313.
7. Carmichael J, Fink U, Russell RCG, Spittle MF. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Eur J Cancer 1993; 29A (suppl 6): S101 (abstr 541).
8. Casper ES, Green MR, Kelsen DP, Heelan RT. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
9. Moore M, Andersen J, Burris H, Tarasoff P. A randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1995; 14: 199 (abstr 473).
10. Rothenberg ML, Moore MJ, Cripps CM, Andersen J. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7 (suppl 4): 347-53.
11. Lund B, Hansen OP, Theilade K, Hansen M. Phase II study of gemcitabine (2′,2′-difluorodeoxycitidine) in previously treated ovarian cancer. J Natl Cancer Inst 1994; 86: 1530-3.
12. Neijt JP, Bauknecht T, Kaufman M, et al. Gemcitabine in pretreated ovarian cancer. Ann Oncol 1996; 7 (suppl 5): 70 (abstr 329).
13. Underhill C, Parnis FX, Highley M, Ahern J, Lund B. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). Ann Oncol 1996; 7 (suppl 5): 69 (abstr 324).
14. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynaecol Oncol 1996; 63 (suppl 1): 89-93.
15. Carmichael J, Possinger K, Philip P, et al. Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1993; 12: 64 (abstr 57).
16. Blackstein M, Vogel C, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer 1997; 33 (suppl 10): S149 (abstr 664).
17. Spielmann M, Pouillart P, Espié M, et al. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline containing regimens. Ann Oncol 1996; 7 (suppl 5): 23 (abstr 99P).
18. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously un-treated extensive small cell lung cancer A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann Oncol 1994; 5: 283-5.
19. De Lena M, Gridelli C, Lorusso V, et al. Gemcitabine activity (objective responses and symptom improvement) in resistant stage IV bladder cancer. Proc Am Soc Clin Oncol 1996; 15: 246 (abstr 622).
20. Stadler WM, Murphy B, Kaufman D, et al. Phase II study of gemcitabine (GEM) plus cisplatin (CDDP) in metastatic urothelial cancer (UC). Proc Am Soc Clin Oncol 1997; 16: 323a (abstr 1152).
21. Moore MJ, Tannock I, Ernst S, Huan S, Murray N. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 1996; 15: 250 (abstr 637).
22. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 543-7.
23. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821-6.
24. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. A multicenter phase II trial with gemcitabine in on-small cell lung cancer (NSCLC). Lung Cancer 1994; II (suppl 1): 121 (abstr 461).
25. Kaye SB. Gemcitabine current status of phase I and II trials. J Clin Oncol 1994; 12: 1527-31.
26. Abratt RP, Bazwoda WR, Falkson G, et al. Efficacy and safety of gemcitabine in non-small cell lung cancer a phase II Study. J Clin Oncol 1994; 12: 1535-40.
27. Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer past present and future. Semin Oncol 1997; 24: 440-54.
28. Doll DC, Weiss RB, Issell BF. Mitomycin: ten years after approval for marketing. J Clin Oncol 1985; 3 (suppl 2): 276-86.
29. Pavlakis N, Bell BR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-91.
30. Schmoll H. Review of etoposide single-agent activity. Cancer Treat Rev 1982; 9 (suppl A): 21-30
31. Dollery C, ed. Ifosfamide therapeutic drugs. Edinburgh: Churchill Livingstone 1991; 1: 110-5.
32. Spencer CM, Fanlds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1974; 48: 794-847.
33. Massidda B, Fenu MA, Ionta MT, et al. Early detection of the anthracycline-induced cardiotoxicity. A non-invasive haemodynamic study. Anticancer Res 1997; 17: 663-8.
34. Lipschultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Eng J Med 1991; 324: 808-15.
35. Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer effective and cardiotoxic. Ann Oncol 1996; 7 (suppl 7): 687-93.
36. Dechant KL, Brogden RN, Pikington R. Ifosfamide/Mesna. A review of its antineoplastic antivity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991; 42: 428-67.
37. Henwood JM, Brodgen RN. Etoposide - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in combination chemotherapy of cancer. Drugs 1990; 39 (suppl 3): 438-70.
38. Crooke ST, Bradnen WT. Mitomycin C - a review. Cancer Treat Rev 1976; 3: 121-39.
39. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984; 100: 704-13.
40. Prestayko AW, D'Aunst JC, Issel BF, et al. Cisplatin (cisdiamminedichloro platinuim II). Cancer Treat Rev 1979; 6: 17-39.
41. Brade WP, Herdrich K, Valini M. Ifosfamide - pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12: 1-47.